Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • JJP
    Junior Member
    • Jul 2013
    • 3

    #1

    Tophat2 normal alignment rate

    Hi there, I am a complete RNA seq newbie, so let me excuse myself preventively for any stupid questions.

    Recently I started working with mouse RNA seq data, after running the data though Tophat2 I got a 91.0% overall read alignment rate and a 83.1% concordant pair alignment rate.

    Could somebody with more experience in the field tell me if this are good alignment values, and if not which are the normal values I should expect ?

    Thanks in advanced.
  • Jon_Keats
    Senior Member
    • Mar 2010
    • 279

    #2
    what read length, not bad if 100mers

    Comment

    • JJP
      Junior Member
      • Jul 2013
      • 3

      #3
      Sorry I knew I had forgotten to mention something, the reads have a length of 101.
      Last edited by JJP; 07-18-2013, 04:56 AM.

      Comment

      • jp.
        Senior Member
        • Jul 2013
        • 142

        #4
        Dear Jon
        I have posted the same problem here;
        Discussion of next-gen sequencing related bioinformatics: resources, algorithms, open source efforts, etc

        any solution ?

        Originally posted by Jon_Keats View Post
        what read length, not bad if 100mers

        Comment

        • rnastar
          Member
          • Aug 2013
          • 13

          #5
          I just finished running tophat on about 20 cancer samples and my concordant pair alignment rate ranged between 50-60% for 50 bp reads. Should I be worried? Will this have an impact on the downstream cufflinks/cuffdiff analysis?

          Comment

          • westerman
            Rick Westerman
            • Jun 2008
            • 1104

            #6
            I presume you are talking about *human* samples. The 50-60% rate is low. I suspect that since the samples are more-or-less uniform in their mapping rate then you won't have too many problems with cufflinks/cuffdiff aside from not having as much data to work with.

            Did you run non-cancer controls? Or are those part of the "20" you mention above. How about replicates -- technical and biological?

            Comment

            • rnastar
              Member
              • Aug 2013
              • 13

              #7
              Yes, human samples. We did run non-cancer controls but they did not have this problem. What do you think this means? Is this more a reflection of biology or an indication of a technical issue? We do not have any technical replicates, only biological.

              Comment

              • westerman
                Rick Westerman
                • Jun 2008
                • 1104

                #8
                The lack of technical replicates is not a big concern -- although they can help troubleshooting usually the technical process is flawless. Although when problems do occur you really wish that you had technical reps. :-)

                As for the question "is a 50-60% concordant rate normal for cancer samples when the non-cancer samples have a higher concordant rate?" ... I am going to have to skip on answering this. I simply do not have enough experience with human cancer samples to say one way or another. Cancer genome rearrangements can be widespread so may 50-60% if expected. Can anyone with more human experience chime in?

                BTW: You may wish to make a new thread on this topic with the keywords "human"
                and "cancer" in it. That might attract more knowledgeable people.

                Comment

                Latest Articles

                Collapse

                • SEQadmin2
                  Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
                  by SEQadmin2



                  Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

                  Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
                  ...
                  10-14-2026, 09:55 AM
                • SEQadmin2
                  New Genomics Technologies Take Aim at Long-Standing Limits
                  by SEQadmin2


                  Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

                  We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
                  ...
                  09-28-2026, 10:25 AM

                ad_right_rmr

                Collapse

                News

                Collapse

                Topics Statistics Last Post
                Started by SEQadmin2, Yesterday, 11:13 AM
                0 responses
                19 views
                0 reactions
                Last Post SEQadmin2  
                Started by SEQadmin2, Yesterday, 10:48 AM
                0 responses
                18 views
                0 reactions
                Last Post SEQadmin2  
                Started by SEQadmin2, 10-15-2026, 10:52 AM
                0 responses
                36 views
                0 reactions
                Last Post SEQadmin2  
                Started by SEQadmin2, 10-14-2026, 05:39 AM
                0 responses
                42 views
                0 reactions
                Last Post SEQadmin2  
                Working...